Trial reportNeuropsychiatric disease and treatment2025
A Pilot Study of Remote Ischemic Conditioning in Preventing Post-Stroke Depression.
Trial report in Neuropsychiatric disease and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Post-stroke depression (PSD) constitutes a significant complication that influences both patient survival and functional recovery following a stroke. Despite its prevalence, PSD still lacks a long-term, safe and effective treatment measure. Remote ischemic conditioning (RIC) is a simple and noninvasive procedure that exert neuroprotective effects. This pilot study aims to investigate the efficacy, safety, and feasibility of RIC as a preventive measure against PSD. Methods: Acute ischemic stroke patients within 15 days post-event were considered eligible for study enrollment. Fifty participants were recruited and underwent daily RIC treatments for a 12-month period. Depressive symptoms were assessed utilizing the Patient Health Questionnaire-9 (PHQ-9) and the Hamilton Depression Rating Scale (HAMD) at baseline, as well as at 1, 3, 6, and 12-months post-intervention. Results: The study found a gradual improvement in depressive symptoms among the 50 patients who completed the study over the 12-month treatment period, as evidenced by a consistent decline in pertinent scores. Moreover, merely two patients experienced mild adverse reactions. Conclusion: The study's outcomes indicate that RIC is safe, well-tolerated, and feasible as a preventive measure for PSD. Consequently, it is advisable to conduct a comprehensive randomized controlled trial to further evaluate the effectiveness and safety of RIC in preventing PSD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.